CD20 Monoclonal Antibody (QCH6A7), APC, eBioscience™, Invitrogen™

Description

• Description: The monoclonal antibody QCH6A7 reacts with mouse CD20
• CD20 is a B cell specific, 32-kDa membrane protein that is expressed on late pro-B cells through memory B cells in the B cell lineage
• CD20 is not found on hematopoietic stem cells, early pro-B cells or later mature plasma cells
• CD20 is involved in intracellular calcium regulation and plays a role in B cell proliferation
• CD20 is intially expressed after the induction of CD19 during development and is coexpressed with IgM during the pre-B to immature B cell transition in bone marrow
• Expression of CD20 increases during maturation with almost all mature B cells expressing some level of CD20
• Unlike other B cell antigens, CD20 is not shed or internalized upon antibody binding
• Monoclonal antibodies against the CD20 antigen may be used to deplete B cells and CD20 has proven to be an effective immunotheraputic target in B cell lymphomas and several autoimmune diseases including rheumatoid arthritis and type I diabetes
• CD20 consists of 4 transmembrane domains and a 44 amino acid extracellular domain which contains the QCH6A7 epitope
• Staining with clone QCH6A7 provides significantly improved staining intensity compared to clone AISB12 in flow cytometric assays
• Applications Reported: This QCH6A7 antibody has been reported for use in flow cytometric analysis
• Applications Tested: This QCH6A7 antibody has been tested by flow cytometric analysis of mouse bone marrow cells and mouse splenocytes
• CD20 is a non-glycosylated surface phosphoprotein that has a molecular weight range of 33-37 kDa depending on the degree of phosphorylation
• CD20 is expressed on mature and most malignant B cells, in a subpopulation of T lymphocytes and follicular dendritic cells
• CD20 expression on B cells is synchronous with the expression of surface IgM and it regulates transmembrane calcium conductance, cell cycle progression and B-cell proliferation
• CD20 is also associated with lipid rafts, but the intensity of this association depends on extracellular triggering, employing CD20 conformational change, and/or BCR (B cell antigen receptor) aggregation
• After the receptor ligation, BCR and CD20 colocalize and then rapidly dissociate before BCR endocytosis, whereas CD20 remains at the cell surface
• CD20 serves as a useful target for antibody-mediated therapeutic depletion of B cells, as it is expressed at high levels on most B-cell malignancies, but does not become internalized or shed from the plasma membrane following monoclonal antibody treatment
• Diseases associated with CD20 dysfunction include Ms4a1-related common variable immune deficiency.